Editorial: Targeting the PD-1/PD-L1 Cancer Immune Evasion Axis: Challenges and Emerging Strategies

Affiliations

• ¹ Institutes of Biomedical Sciences, Zhongshan-Xuhui Hospital, Key Laboratory of Epigenetics and Metabolism, Fudan University, Shanghai, China.
• ² Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
• ³ The State Key Laboratory of Biotherapy, Sichuan University West China Hospital, Chengdu, China.
• ⁴ Division of Nanomedicine, Department of Medicine, University of California, Los Angeles, Los Angeles, CA, United States.